The metabolic cost of lowering blood pressure with hydrochlorothiazide

Background: The landmark Antihypertensive and Lipid-Lowering treatment to prevent Heart Attack Trial (ALLHAT) placed a new spotlight on thiazide diuretics as the first-line therapy for hypertension. This is concerning as thiazide-diuretics may contribute to comorbidities associated with the current epidemic of obesity. Previous randomized clinical trials have linked thiazide diuretic treatment to insulin resistance, metabolic syndrome, and increased incidence of type 2 diabetes. Methods: This proof of concept, longitudinal, randomized, double-blind study evaluated the effects of the angiotensin II receptor blocker Valsartan and the specific thiazide diuretic Hydrochlorothiazide (HCTZ) on hepatic triglyceride level (primary outcome), as well as triglyceride levels within other organs including the heart, skeletal muscle, and pancreas. Additionally, we evaluated whether myocardial function, insulin sensitivity, and insulin secretion were affected by these treatments. Results: Hepatic TG levels increased by 57% post HCTZ treatment: Delta hTG (HCTZ) = 4.12% and remained unchanged post Valsartan treatment: Delta hTG (V) = 0.06%. The elevation of hepatic TG levels after HCTZ treatment was additionally accompanied by a reduction in insulin sensitivity: Delta SI (HCTZ) = -1.14. Treatment with Valsartan resulted in improved insulin sensitivity: Delta SI (V) = 1.24. Treatment-induced changes in hepatic TG levels and insulin sensitivity were statistically significant between groups (p(hTG) = 0.0098 and p(SI) = 0.0345 respectively). Disposition index, DI, remained unchanged after HCTZ treatment: Delta DI (HCTZ) = -141 but it was increased by a factor of 2 after treatment with Valsartan: Delta DI (V) = 1018). However, the change between groups was not statistically significant. Both therapies did not modify abdominal visceral and subcutaneous fat mass as well as myocardial structure and function. Additionally, myocardial, pancreatic, and skeletal muscle triglyceride deposits remained unchanged in both therapeutic arms. Conclusions: Our findings are two-fold and relate to hepatic steatosis and insulin sensitivity. HCTZ treatment worsened hepatic steatosis measured as hepatic triglyceride content and reduced insulin sensitivity. Valsartan treatment did not affect hepatic triglyceride levels and improved insulin sensitivity. The results of this study reinforce the message that in patients at risk for type 2 diabetes it is particularly important to choose an antihypertensive regimen that lowers blood pressure without exacerbating patient's metabolic profile.